Phaseline

Targets › DLK1

DLK1 (Protein delta homolog 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2027.

May have a role in neuroendocrine differentiation. (UniProt, P80370)

Open in Phaseline: the race on DLK1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chiome BioscienceCBA-1205
anti-DLK1 monoclonal antibody
DLK1Phase 1Solid TumorsJun 2027

Conditions

Solid Tumors (1)

Modalities

small molecule (1)

Companies

Chiome Bioscience (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.